Possible role of the receptor of advanced glycation end products (RAGE) in the clinical course of prostate neoplasia in patients with and without type 2 diabetes mellitus

2020 ◽  
Author(s):  
Gamze Akkus ◽  
Volkan Izol ◽  
Fesih Ok ◽  
Mehtap Evran ◽  
Merve Inceman ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Advanced Glycation End Products ◽  
Clinical Course ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

Association of advanced glycation end products with peri-implant inflammation in prediabetes and type 2 diabetes mellitus patients

2018 ◽  
Vol 20 (4) ◽  
pp. 535-540 ◽  
Author(s):  
Mohammed Alrabiah ◽  
Khulud Abdulrahman Al-Aali ◽  
Zeyad H. Al-Sowygh ◽  
Abdulelah M. Binmahfooz ◽  
Sameer A Mokeem ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Advanced Glycation End Products ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Serum Levels of Antibodies to Advanced Glycation End Products in Patients with Type 2 Diabetes Mellitus and Hypertension

Folia Medica ◽  
2020 ◽  
Vol 62 (2) ◽  
pp. 295-301
Author(s):  
Asparuh Nikolov ◽  
Alexander Blazhev ◽  
Maria Tzekova ◽  
Konstantin Kostov ◽  
Nikola Popovski
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Advanced Glycation End Products ◽  
Serum Levels ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Group 1

Background and Aims: Proteins containing advanced glycation end products are highly immunogenic and anti-advanced glycation end products antibodies (anti-AGEs antibodies) are found in the sera of diabetics. Materials and methods: Enzyme-linked immunosorbent assay (ELISA) was used for measuring levels of anti-advanced glycation end products antibodies in sera of 93 patients with type 2 diabetes mellitus and arterial hypertension (mean age 61.4&plusmn;11.3 years, diabetes duration 9.88&plusmn;3.12 years; hypertension duration 9.28&plusmn;4.98). These values were compared to serum anti-AGEs antibodies in 42 age and sex matched controls. Diabetics were divided in two groups according to presence or absence of microangiopathy, group 1 (n=67) and group 2 (n=26), respectively. Results: Serum levels of anti-AGEs antibodies in patients with type 2 diabetes mellitus and arterial hypertension were statistically significantly higher than those in the control group (1.39&plusmn;0.39 vs. 1.05&plusmn;0.32), (p<0.05). Group 1 showed significantly higher levels of anti-AGEs antibodies than those of healthy controls (1.53&plusmn;0.14 vs. 1.05&plusmn;0.32), (p<0.01). Anti-AGEs antibodies levels were higher in patients with microvascular complications than these in patients without complications. Anti-AGEs antibodies correlate with diastolic blood pressure (r=0.26, p=0.05) and body mass index (r=0.37, p=0.03). We found significantly higher percentage of positive patients for anti-AGEs antibodies (mean+2SD) in group 1 than in group 2. Conclusion: Determining the levels of serum anti-AGEs antibodies can help physicians make early diagnosis and prognosis of the severity of late diabetic complications in hypertensive patients.

Sign in / Sign up

Export Citation Format

Share Document